ITB-MED
Biotechnology Research
Se
47 employees
- Employees
- 47
- Contacts
- 2
- Emails
- 2
- Phones
- 1
ITB-MED Overview
- Headquarters
- Se
- Website
- itb-med.com
- Industry
- Biotechnology Research
- Employees
- 47
- Founded
- 2016
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About ITB-MED
ITB-MED is developing the proprietary antagonistic CD2-directed monoclonal antibody, TCD601 (siplizumab), for several indications. ITB-MED is wholly committed to advancing and exploring the potential of TCD601, with a particular focus on its applications in transplantation and autoimmunity. The efforts extend to comprehensive worldwide clinical trials. ITB-MED is actively investigating further preclinical therapies to expand the reach of its novel immune-modulating approaches.
ITB-MED Contact Details
- People in AeroLeads
- 4
- With contact data
- 2
- Email contacts
- 2
- 50.0% coverage
- Phone contacts
- 1
- 25.0% coverage
ITB-MED Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Marsha Miller | Vice President, Head of Regulatory |
View
|
|
| Anna-Karin Lindblad | Stockholm, Stockholm County, Sweden |
Email
|
|
| Leslie Zacks | Chief Legal and Compliance Officer | New York, United States |
Email
Phone
|
| Alan Slade | Senior Vice President, Global Head |
View
|
Employees by Management Level
Executive
3 profiles
Compare Similar Companies to ITB-MED
AstraZeneca
Pharmaceutical Manufacturing
AbbVie
Pharmaceutical Manufacturing
Semcon
Information Technology & Services
Atlas Antibodies
Biotechnology Research
ABC Labs
Medical Practices
Pixelgen Technologies
Biotechnology Research
Sand Clinic
Hospitals And Health Care
Nefro Health
Investment Management
Nefro Health
Medical Practices
Forskaren
Real Estate